Zobrazeno 1 - 10
of 680
pro vyhledávání: '"B Claggett"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
K McDowell, J Simpson, P S Jhund, W T Abraham, B Claggett, J Cunningham, A S Desai, L Kober, M Prescott, J L Rouleau, K Swedberg, M R Zile, S D Solomon, M Packer, J J V McMurray
Publikováno v:
European Heart Journal. 43
Background Although multiple novel biomarkers have individually been shown to predict outcomes in patients with HFrEF, the value of these over and above conventional clinical and laboratory variables, plus natriuretic peptides, is uncertain. Purpose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a82941e29f51d2c4025bc08c048e8398
https://doi.org/10.1093/eurheartj/ehac544.914
https://doi.org/10.1093/eurheartj/ehac544.914
Autor:
F McCausland, A Singh, B Claggett, K Carroll, J Wittes, J J V McMurray, V Perkovic, S Snappin, R Lopes, S Solomon
Publikováno v:
European Heart Journal. 43
Background Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) represent a potential new therapeutic option to treat anaemia of chronic kidney disease (CKD). Purpose In the recent ASCEND-ND trial (NCT02876835)1, conducted in patients wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::da205521ad2e482ae87db6de4173f407
https://doi.org/10.1093/eurheartj/ehac544.2621
https://doi.org/10.1093/eurheartj/ehac544.2621
Autor:
E Platz, B Claggett, K S Jering, A Kovacs, M Cikes, E B Winzer, A Rad, M Lefkowitz, J Gong, L Kober, J J V McMurray, S D Solomon, A Shah
Publikováno v:
European Heart Journal. 43
Background The PARADISE-MI trial examined the efficacy of sacubitril/valsartan in patients with acute myocardial infarction (AMI) complicated by reduced left ventricular ejection fraction (LVEF), pulmonary congestion or both. Little is known about th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a93072f09d552f1b87ec836152e137df
https://doi.org/10.1093/eurheartj/ehac544.345
https://doi.org/10.1093/eurheartj/ehac544.345
Autor:
K Jering, B Claggett, M A Pfeffer, C Granger, L Kober, E F Lewis, A P Maggioni, D L Mann, J J V McMurray, M F Prescott, J L Rouleau, S D Solomon, P G Steg, D Von Lewinski, E Braunwald
Publikováno v:
European Heart Journal. 43
Background/Introduction N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a marker of ventricular wall stress and a potent predictor of death and heart failure (HF) across multiple populations (from healthy insurance applicants to various dise
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::80e4f41b491f2304767303bf60b25af6
https://doi.org/10.1093/eurheartj/ehac544.1324
https://doi.org/10.1093/eurheartj/ehac544.1324
Autor:
M Cikes, K Jering, B Claggett, O Amir, A J Cadena Bonfanti, M C Cho, C Granger, L M Gullestad, H L Kao, J Morais, J F Tanguay, M Tokmakova, P Widimsky, S D Solomon
Publikováno v:
European Heart Journal. 43
Background Atrial fibrillation or flutter (AFF) is common in both patients with myocardial infarction (MI) and those with heart failure (HF). However, its impact on the risk of adverse outcomes in MI complicated by either reduced LVEF and/or transien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::86e043adb83096c5b7ef2c726e7a0fdd
https://doi.org/10.1093/eurheartj/ehac544.1178
https://doi.org/10.1093/eurheartj/ehac544.1178
Autor:
J Cunningham, L Zhang, B Claggett, W Abraham, P Jhund, L Kober, M Packer, J Rouleau, M Zile, M Prescott, M Mendelson, M Lefkowitz, J McMurray, S Solomon, W Chutkow
Publikováno v:
European Heart Journal. 43
Background Though current heart failure (HF) biomarkers are highly prognostic, systematically characterizing associations between circulating proteins and risk of subsequent events may improve clinical risk prediction and illuminate new biological pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c32f44f2812bca6c9faf0a9821fe0893
https://doi.org/10.1093/eurheartj/ehac544.917
https://doi.org/10.1093/eurheartj/ehac544.917
Autor:
M Schou, B Claggett, A Fernandez, G Filippatos, C Granger, K Jering, A Maggioni, F McCausland, J Nunez Villota, J L Rouleau, F G Mody, P Van Der Meer, D Vinereanu, Y Zhou, L Kober
Publikováno v:
European Heart Journal. 43
Background Mineralocorticoid receptor antagonists (MRAs) reduce the risk of cardiovascular death or heart failure admission in patients with myocardial infarction (MI) and left ventricular systolic dysfunction (LVSD) combined with either heart failur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::37b63045aee93737a288bb3bf24b1f38
https://doi.org/10.1093/eurheartj/ehac544.977
https://doi.org/10.1093/eurheartj/ehac544.977
Autor:
A Butters, C Arnott, J Sweeting, B Claggett, J Atherton, C Semsarian, N K Lakdawala, C Y Ho, J Ingles
Publikováno v:
European Heart Journal. 43
Background Patient sex has been associated with differences in disease penetrance and clinical expression in HCM. We sought to investigate sex-disaggregated differences in risk factors for adverse outcomes in a large international HCM registry. Metho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7bc6467ae76a238dda4d0090355db08e
https://doi.org/10.1093/eurheartj/ehac544.2497
https://doi.org/10.1093/eurheartj/ehac544.2497